DX-9065 Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413978

CAS#: 150612-55-8 (free base)

Description: DX-9065 Free Base is a biochemical

Chemical Structure

img
DX-9065 Free Base
CAS# 150612-55-8 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 413978
Name: DX-9065 Free Base
CAS#: 150612-55-8 (free base)
Chemical Formula: C26H28N4O3
Exact Mass: 444.22
Molecular Weight: 444.540
Elemental Analysis: C, 70.25; H, 6.35; N, 12.60; O, 10.80

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 150611-80-6 (HCl)   150612-55-8 (free base)  

Synonym: DX-9065 Free Base; DX9065; DX 9065

IUPAC/Chemical Name: (alphaS)-7-(Aminoiminomethyl)-alpha-(4-(((3S)-1-(1-iminoethyl)-3-pyrrolidinyl)oxy)phenyl)-2-naphthalenepropanoic acid

InChi Key: AGRCGQSFFMCBRE-ZEQRLZLVSA-N

InChi Code: InChI=1S/C26H28N4O3/c1-16(27)30-11-10-23(15-30)33-22-8-6-19(7-9-22)24(26(31)32)13-17-2-3-18-4-5-20(25(28)29)14-21(18)12-17/h2-9,12,14,23-24,27H,10-11,13,15H2,1H3,(H3,28,29)(H,31,32)/t23-,24-/m0/s1

SMILES Code: O=C(O)[C@H](C1=CC=C(O[C@@H]2CN(C(C)=N)CC2)C=C1)CC3=CC=C4C=CC(C(N)=N)=CC4=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 444.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fujii Y, Kanamaru T, Kikuchi H, Yamashita S, Sakuma S. Enteric-coated tablets improve oral bioavailability of DX-9065, a novel anticoagulant. Eur J Pharm Sci. 2011 Mar 18;42(4):392-9. doi: 10.1016/j.ejps.2011.01.003. Epub 2011 Jan 14. PMID: 21238588.

2: Fujii Y, Takahashi M, Ishiguro T, Sakuma S, Uekama K, Irie T. Cyclodextrins improve oral absorption of a novel factor Xa inhibitor by interfering with interaction between the drug and bile acids in rats. J Pharm Pharmacol. 2013 Nov;65(11):1598-606. doi: 10.1111/jphp.12137. Epub 2013 Sep 5. PMID: 24118066.

3: Fujii Y, Kanamaru T, Kikuchi H, Nakagami H, Yamashita S, Akashi M, Sakuma S. Improvement of low bioavailability of a novel factor Xa inhibitor through formulation of cationic additives in its oral dosage form. Int J Pharm. 2011 Dec 15;421(2):244-51. doi: 10.1016/j.ijpharm.2011.09.046. Epub 2011 Oct 5. PMID: 22001539.

4: Kaiser B. DX-9065a, a direct inhibitor of factor Xa. Cardiovasc Drug Rev. 2003 Summer;21(2):91-104. doi: 10.1111/j.1527-3466.2003.tb00108.x. PMID: 12847561.

5: Murayama N, McMahon H, Young CG, McCracken NW, Okamura Y, Hakusui H, Tanaka M. Pharmacokinetics of the anticoagulant 14C-DX-9065a in the healthy male volunteer after a single intravenous dose. Xenobiotica. 2000 May;30(5):515-21. doi: 10.1080/004982500237514. PMID: 10875684.

6: Kaiser B. DX-9065a Daiichi. Curr Opin Investig Drugs. 2003 Sep;4(9):1105-12. PMID: 14582456.

7: Matsushita K, Imamura T, Tomikawa M, Tancharoen S, Tatsuyama S, Maruyama I. DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa. J Periodontal Res. 2006 Apr;41(2):148-56. doi: 10.1111/j.1600-0765.2005.00853.x. PMID: 16499718.

8: Herbert JM, Bernat A, Dol F, Hérault JP, Crépon B, Lormeau JC. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J Pharmacol Exp Ther. 1996 Mar;276(3):1030-8. PMID: 8786532.

9: Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost. 1994 Mar;71(3):314-9. PMID: 8029795.

10: Fujii Y, Takahashi M, Morita H, Kikuchi H, Aramaki Y, Amidon GL. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant. Drug Metab Pharmacokinet. 2007 Feb 25;22(1):26-32. doi: 10.2133/dmpk.22.26. PMID: 17329908.